Search details
1.
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.
Blood
; 143(23): 2401-2413, 2024 Jun 06.
Article
in English
| MEDLINE | ID: mdl-38427753
2.
miR-17-92 cluster-BTG2 axis regulates B-cell receptor signaling in mantle cell lymphoma.
Cancer Sci
; 115(2): 452-464, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38050664
3.
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
Cancer Sci
; 115(6): 2002-2011, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38498976
4.
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
Br J Haematol
; 204(3): 849-860, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37996986
5.
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Cancer Immunol Immunother
; 73(7): 135, 2024 May 17.
Article
in English
| MEDLINE | ID: mdl-38758239
6.
Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.
Haematologica
; 2024 Jun 06.
Article
in English
| MEDLINE | ID: mdl-38841789
7.
Skeletal muscle index impacts the treatment outcome of elderly patients with diffuse large B cell lymphoma.
Hematol Oncol
; 42(1): e3252, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38287527
8.
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Hematol Oncol
; 42(3): e3272, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38595316
9.
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
Ann Hematol
; 103(2): 475-488, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37695378
10.
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Ann Hematol
; 2024 Mar 16.
Article
in English
| MEDLINE | ID: mdl-38492020
11.
Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas.
Cancer Sci
; 114(12): 4691-4705, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37840379
12.
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01.
Cancer Sci
; 114(5): 2098-2108, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36793248
13.
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
Cancer Sci
; 114(4): 1297-1308, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36610002
14.
Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma.
Br J Haematol
; 203(3): 426-438, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37584109
15.
Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma.
J Hum Genet
; 68(7): 507-514, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-36882509
16.
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Haematologica
; 108(3): 811-821, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36200417
17.
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Cancer Sci
; 113(12): 4267-4276, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36052883
18.
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma.
Ann Hematol
; 101(5): 979-989, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35244756
19.
Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial.
Jpn J Clin Oncol
; 52(6): 583-588, 2022 May 31.
Article
in English
| MEDLINE | ID: mdl-35353186
20.
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
Int J Mol Sci
; 23(9)2022 Apr 23.
Article
in English
| MEDLINE | ID: mdl-35563085